DSG3 and acquired polycythemia vera: The main finding of this study was that rituximab treatment improved severe refractory PV, as demonstrated with decreases in the PDAI, anti-Dsg1 and anti-Dsg3 antibody titers, percent of CD20 positive cells, and required corticosteroid dose to control the disease.